welcome to im department meeting! gadolinium based contrast exposure and risk of nephrogenic...
TRANSCRIPT
Welcome to IM Department Meeting!
Gadolinium Based Contrast Exposure and Risk of Nephrogenic Systemic Fibrosis
Tonight’s Facilitators:Barbara Doerr, DOWilliam Myers, DOStaci Smith, DOMichelle Cacek, DO
Nephrogenic Systemic Fibrosis (NSF)
o originally named nephrogenic fibrosing dermopathy (NFD)
o manifestations initially thought to be confined to the skin
o systemic fibrosis on autopsy (NSF)oskeletal muscles ,diaphragm ,pleura ,dura
mater, pericardium & myocardium
Nephrogenic Systemic Fibrosis (NSF)
o predominately in pts with acute kidney injury or severely impaired renal function o CrCl less than 30
o no predilection for age, race, gender ,or location
o typically middle aged ptso reported in 8 yo children, as well as elderly
What’s the risk?
o risk of NSF estimated at 4.3 cases per 1,000 dialysis patients per year
o about 2.4 % for each time a CKD pt is exposed to gadolinium
o balancing benefit and risko majority of pts who receive Gd do not
develop NSF
What’s the issue with NSF?
o avoidance of GBCA’s o limited radiological studies
o roadblocks to specific dx
o litigation opportunities
September 12, 2007
Boxed Warning
o Gadolinium based contrast agents increase risk of NSF in pts with:o acute and chronic renal failure (GFR <
30)o acute renal insuffciency of any severity
due to hepatorenal syndrome or in perioperative liver transplant period
What is Gadolinium?
o nonionic, hyperosmolar (650 mosmol/kg) contrast agent
o metal with powerful magnetic properties o contrast for MR imaging or MR angiographyo chelates are excreted exclusively by the
kidney
Gadolinium Half Life
o 1.3 hrs if healthyo 10 hrs at GFR of 20 - 40 mL/mino 34 hrs if ESRDo 1.9 - 2.6 hrs if HD follows administration
Gadolinium Based Contrast Agents
o Omniscano launched in the U.S. in 1993 by GE
o Magnevisto MultiHanceo OptiMARKo ProHance
Risk factors for NSFo renal impairmento hypercoagulable stateo thrombotic eventso recent vascular studyo transplant failure
Signs and Symptoms of NSF
o burning skino itchy skino swelling o tight and hard skin o red or dark skin
patcheso contractures
o stiffness in joints o trouble moving
extremities o pain deep in the boneso muscle weaknesso “woody” feel of skino yellow scleral plaques
NSF Upper Extremity
o thick, hardened skin
o brawny hyperpigmentation
o distinct papules
o subcutaneous nodules
NSF Upper Extremityo soft-tissue swelling o flexion contractures of hand
o slightly raised and erythematous nodular plaqueso linear, confluent regions of fibrosis
NSF
Differential Diagnosis
o scleroderma / systemic sclerosis o eosinophilic fasciitis o eosinophilia–myalgia syndrome
Differential Diagnosis
o Unlike sclerodermao NSF spares the face o lacks the serologic markers of
sclerodermao symmetrical lesions
oprefers trunk and extremities
Punch Biopsy : Skin
widening of subcutaneous septae w/ thick collagen bundles
Histological Findings and Pathogenesis
o thick collagen bundles with surrounding clefts
o mucin depositiono increased fibrocytes and elastic fiberso increased factor XIIIa and mononucleated
cells
Topic Development: PICO
o PPatient Population
o IIntervention or Exposure
o CComparison Intervention
o OOutcome
Question ???
o What degree of kidney disease should we not use gadolinium based contrast agents ?
Article
o Nephrogenic Fibrosing Dermopathy/ Nephrogenic Systemic Fibrosis: Report of a New Case with Literature Review
o Daram, et al. AJKD, Vol 46, No 4, 2005, pp 754-759.
Evidence Based Medicine
o Nephrogenic Fibrosing Dermopathy /Nephrogenic Systemic Fibrosis: Report of a New Case with Literature Review
o Daram ,et al. o AJKD 2005
Introduction- NSF: Report of a New Case
o first cases of NSF recognized in 2000o renal dysfunction pts
o regardless of causeo not just HD pts, PD pts as well
o other associations:o vascular sxo vascular thrombosiso scleral plaques
The Patient: NSF: Report of a New Case
o 39 yo AAM o ESRD on HD d/t HTN for 8 yrso multiple medical problems
oantiphospholipid ab syndrome
o no other rheumatologic history o 3 yrs before hospital admission
ostiff fingers and armsothickening skin on calves and thighsorapid progression to contractures
The Patient- NSF: Report of a New Case
o pt’s lab data -p 755o fibrosis around
translumbar HD catho pt expired after 45
min of ACLS
o autopsy resultso extensive fibrosiso plaque like changes
across chest, extremities
o contractureso thickened pleurao dense collagenous
bandso fibrotic cardiac tissue
NSF: Report of a New Case
o taut, waxy appearanceo cobblestone pattern o fig 1B
NSF: Report of a New Case
o chest wall w/thick dermis
o dense white fibrous bands in septa
NSF: Report of a New Case
haphazardly arranged collagen bundles w/ clefts
NSF: Report of a New Case
o diaphragm sectiono fibrous bands o fibroblast like cells
NSF: Report of a New Case
dendritic projections on CD34 cells CD45 RO cells
Discussion- NSF: Report of a New Case
o NFD is not merely a cutaneous diseaseo systemic manifestations
omuscle, pleura, diaphragm, myo and pericardium
o initiating factors in NSFo tissue injuryo hypercoagulable state
Discussion - NSF: Report of a New Case
o NSF involves aberrant fibrocyte recruitmento decrease EPO due to fibrogenic properties
o NO consistent treatment proven effective
Articleo Nephrogenic Systemic Fibrosis After
Exposure to Gadolinium in Patients with Renal Failure
o Othersen, J. et al, Nephrology Dialysis Transplantation, Sept 21, 2007, p 1-7.
Evidence Based Medicine
o Nephrogenic Systemic Fibrosis After Exposure to Gadolinium in Patients with Renal Failure
NSF After Gadolinium Exposure
o Purpose:o analyze NSF incidence o association of NSF with gadolinium
exposure in CKD ptsoboth pre-dialysis and dialysis pts
o determine if increased gadolinium exposure increases NSF
NSF After Gadolinium Exposure
o Methods:o 849 total pts in 5 yr time span (2001-2006)o Nephrology at Medical University of SC
odiscussed with Dermatology
o stratified by gadolinium exposureo0, 1, or greater than 1
o statistical association between NSF rate and gad exposure
o statistical association of increasing gad exposure and NSF occurrence
NSF After Gadolinium Exposure
o Methods:o CKD pts NOT on dialysiso 592 pts or 4% had CKD 3 – 4o 6,636 total pts received gad from 2004-
2006o skin bx w/ immunoperoxidase staining for
CD 34
NSF After Gadolinium Exposure
o Results:o 849 total ptso 261 had 354 MRI scans
ow/ gadolinium (Omniscan)o1 time exposure in 191 ptso2 exposures in 53o3 exposures in 13o4 exposures in 5
NSF After Gadolinium Exposure
Gadolinium Exposure
NSF Incidence
Never 0%
One time 1.1%
Greater than one time 2.9%
NSF After Gadolinium Exposure
o Results: Pts on Dialysiso overall NSF rate 0.5% (4 of 261)o 1.5% risk of NSF after one gad exposureo 98.5% did not develop NSFo odds ratio 6.67 w/ one exposure
o44.5 odds ratio with multiple exposures
o skin lesions appeared within 2-3 moo strong statistical association with NSF
and gadolinium exposure
NSF After Gadolinium Exposure
o Results : CKD 3 – 4 ptso no patients discovered to have NSFo incidence estimated at <0.2%o possibly due to only 4% have CKD 3-4
NSF After Gadolinium Exposure
o Conclusions:o NSF incidence is very lowo increased exposure leads to increased risko higher Ca, Phos, and Epo may be
associated with increased NSF incidenceo NO need for gad restriction in CKD 3- 4o monitor skin for 4-6 mo if gad is usedo consider dialysis immediately after
exposureo kidney transplant therapy in future
Concluding Points
o Ao Academic Detailing
o Ro Reminders
o Eo Enticements
o Ao Audit
Concluding Points: Academic Detailso Academic Detailing:
o Medical knowledgeoNSF
o Patient careo Communicationo OMM/OPP o Systems based practice
oPhysician interacts with healthcare systemo Practice based learning
oPhysicians maintain knowledge and skills to provide ongoing pt care
Osteopathic Considerations
o myofascial releaseo indirect techniqueso whole body approach
Osteopathy in Action
o NSF registry o collects info about NSF pts from all over the
worldo General Clinical Research Center at Yale
Universityo e-mail : registermc @juno.com
o CDCo www.cdc.gov
o FDAo 1-800-FDA-1088o www.FDA.gov
Systems Based Practice
o acute NSF: 58089o chronic NSF: 5829o include CKD staging: 585.-o principal procedure
o MRI imaging: 8897
Systems Based Practice
o Cerebral a. occlusion w/ cerebral infarction
DRG: 43491
$5,246.24 Medicare
o Cerebral a. occlusion w/ cerebral infarction
plus acute NSF DRG: 43491,
58089
$7,877.25 Medicare
Reminders
o Carepath in futureo screening baseline kidney fxn / sizeo acute kidney injury vs CKDo CrCl –when not to use gadoliniumo follow-up labs after gadolinium useo when to dialyze ESRD pts if GBCA used
Enticements/ Systems Based Practiceo MRI imaging: DRG 8897o MRI brain w/ contrast: $3,692o MRI brain w/o contrast: $2,255o MRI thoracic/lumbar spine w/ contrast :
$2,465o MRI thoracic/lumbar w/o contrast: $2,144
Audit
o How can we measure outcomes and progress?
o Practice habits changed in the future?
Conclusions : Take Home Points
o interest of pt safetyo balance benefits and risks of GBCA’s
o screen all pts with labs and historyo GBCA’s should NOT be used if CrCl
<30o careful consideration if CrCl <60
o alternative imaging methods
Conclusions: Take Home Points
o monitor for skin manifestations after GBCAo follow labs after administration o do not exceed recommended dose
o 0.1-0.2 mmol/kgo allow time for elimination before
readministration
Please Join Us Next Month
o IM Journal Clubo presented by Dr. Bryano laryngeal reflux and proton pump
inhibitors
References
o Nephrogenic Fibrosing Dermopathy /Nephrogenic Systemic Fibrosis: Report of a New Case with Literature Review.Daram ,et al. AJKD 2005.
o Nephrogenic Systemic Fibrosis After Exposure to Gadolinium in Patients with Renal Failure. Othersen, J. et al, Nephrology Dialysis Transplantation, Sept 21, 2007, p 1-7.
Happy Halloween !!
Trick or treat
References
• www.cdc.gov• www.fda.gov• Gadodiamide-Associated Nephrogenic
Systemic Fibrosis: Why Radiologists Should Be Concerned . Dale R. Broome et al. AJR 2007; 188:586-592.
• Adverse Reactions to Gadolinium Contrast Media: A Review of 36 Cases. Murphy,et al. AJR, Oct 1996:847-849.